Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628039 · ClinicalTrials.gov registry record
Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 622
- Enrollment target
NCT04628039: Completed study, sponsored by VA Office of Research and Development.
NCT04628039 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 622 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04628039 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 622 participants
- Enrollment target
Study Summary
This is study is comprised of three approaches. First, the investigators will conduct a retrospective cohort study to determine factors associated with COVID-19 severity and complications and understand COVID-19 outcomes, including all-cause mortality, post-discharge events, and impacts of rehabilitation services (third aim). The second aim is a mixed-method study and follows COVID-19 patients with repeated surveys to determine patient-reported functional outcomes, health recovery, and rehabilitation needs after COVID-19. The investigators will recruit patients and their informal caregivers for interviews to assess their function and rehabilitation needs.
Primary Outcome
Profile for health-related quality of life. The investigators will summarize this measure with a visual analog score (VAS). The VAS ranges from 0 to 100mm (where 0="the worst health you can imagine"; 100="the best health you can imagine").
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2025-12-31 |
What the finished NCT04628039 record still lists
NCT04628039 is an observational study that tracks outcomes without assigning an intervention. The registered 622 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04628039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04628039 about?
NCT04628039 is a clinical study titled "Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs". This is study is comprised of three approaches. First, the investigators will conduct a retrospective cohort study to determine factors associated with COVID-19 severity and complications and understand COVID-19 outcomes, including all-cause mortality, post-discharge events, and impacts of rehabilit...
What is the current status of trial NCT04628039?
This trial is currently completed. The enrollment target is 622 participants. The study started on 2021-05-27. Estimated completion is 2025-12-31.
Who is sponsoring clinical trial NCT04628039?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712355 · 621 participants · Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI